Remdesivir API CAS NO.1809249-37-3

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Remdesivir is a nucleoside analogue and is an inhibitor of RNA-dependent RNA polymerase (RdRp), which can inhibit viral nucleic acid synthesis against viruses. The current clinical research on Ebola virus infection is in phase II. MERS-infected mice performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. "Remdesivir is active against every coronavirus we have tested. I would be surprised if it is not active against 2019-nCoV," said Mark Denison, an American coronavirus expert. The level is very good, but the sooner the drug is administered, the better.” Yuen Kwok-Yung, a microbiologist at the University of Hong Kong, also believes that Remdesivir is the most promising drug for 2019-nCoV and MERS. However, this drug has not yet been marketed in China. The two top journals voiced in unison that Remdesivir, which was developed to combat the Ebola virus, seems to be a killer to crack 2019-nCoV. Gilead also issued a statement on the drug development actions being taken by the company's chief medical officer, Dr. Merdad Parsey, in response to the 2019 novel coronavirus (2019-nCoV). Dr. Merdad Parsey pointed out in the statement: "In response to the public health event of the 2019 novel coronavirus global outbreak, Gilead is currently in close communication and cooperation with global medical and health regulatory agencies to promote the development of clinical trials of our antiviral drug Remdesivir. Gilead is willing to follow suit. US Food and Drug Administration (FDA), US Centers for Disease Control and Pre-Chemicalbook Prevention (CDC), US Department of Health and Human Services (DHHS), China CDC, World Health Organization (WHO), US National Institute of Allergy and Infectious Diseases (NIAID) and individual researchers and clinicians work together to put our past antiviral drug research and development experience and resources into this battle to help patients and national institutions to jointly fight against 2019-nCoV. Remdesivir is not currently available in any country or country in the world. The region has been approved, and the safety or effectiveness of clinical use has not been proven. However, in order to respond to the needs of clinicians and support the work of some drug regulatory agencies, we have carefully assessed and provided this information that has not been obtained in 2019-nCoV. Any data on the risks and benefits of drugs under development. Gilead has provided Remdesivir to a small number of patients who need emergency treatment but lack treatment drugs. Gilead is currently working closely with the Chinese health authorities and hopes to start a randomized, controlled clinical trial as soon as possible Research to determine whether Remdesivir can be used safely and effectively to treat 2019-nCoV infection. We are also accelerating the laboratory testing of Remdesivir's anti-2019-nCoV activity. Although there is currently no data to prove Remdesivir's anti-2019-nCoV activity, Remdesivir is in The activity data shown in other coronaviruses gives us confidence. Remdesivir has shown good activity against MERS and SARS viruses in vitro and in animal models. These viruses are structurally similar to 2019-nCoV. There are still some on our hands. The clinical data on the emergency treatment of Ebola virus-infected patients with Remdesivir are available for reference.